Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: anavex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2022 | $16.00 → $11.00 | Overweight → Neutral | Cantor Fitzgerald |
| 6/23/2022 | $40.00 | Buy | Berenberg |
| 2/2/2022 | $39.00 → $42.00 | Buy | HC Wainwright & Co. |
| 9/23/2021 | $35.00 | Buy | BTIG Research |
| 6/28/2021 | $25.00 → $39.00 | Buy | HC Wainwright & Co. |
DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
DEF 14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
S-3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first fiscal quarter on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Follow
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains de
NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its fiscal year ended September 30, 2024, on Monday, December 23, 2024. Management will host a conference call on Monday, December 23, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strat
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2024. "We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive result
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2024, on Tuesday, August 6, 2024. Management will host a conference call on Tuesday, August 6, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company's
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2024. "We are encouraged by the very recently issued FDA guidance for Early Alzheimer's disease, which states that one cognitive measurement alone, li
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024. Management will host a conference call on Thursday, May 9, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strate
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2023. "Exciting progress in the field related to treating neurodegenerative diseases highlights the significant potential for our broad therapeutic portfolio and dif
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the successful completion
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025. About Anavex Life Scien
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, "Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, a
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:45 PM (ET) on Monday, April 7th, 2025. A live audio webcast will be accessible th
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first fiscal quarter on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Follow
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing c
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today announced the appointment of David Goldberger, RPh, MLS as Senior Vice President Regulatory Affairs. Mr. Goldberger brings over 40 years of pharmacy practice and pharmaceutical industry experience and has most recently been with Otsuka Pharmaceuticals Research and Development (Otsuka) as Vice President Glo
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board. Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer's and Memory Disorders Program at Barrow Neurological Institute. He is also a professor and the Vice Chair of Research in
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. Dr. Jin will draw on his extensive experience, including recently as the Statistical Team Leader at the U.S. Food and Drug Administration (FDA). Dr. Jin provided statistical review coverage and expertise for neurological
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board. Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study. Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an A
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer, effective immediately. Before joining Anavex over three years ago, Dr. Kaufmann was the Director of the Center for Translational Research a
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously
Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously
BTIG Research initiated coverage of Anavex with a rating of Buy and set a new price target of $35.00
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $39.00 from $25.00 previously
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $25.00 from $17.00 previously
Cantor Fitzgerald resumed coverage of Anavex Life Sciences with a rating of Overweight and set a new price target of $25.00 from $10.00 previously
Cantor Fitzgerald resumed coverage of Anavex Life Sciences with a rating of Overweight
Cantor Fitzgerald reiterated coverage of Anavex Life Sciences with a rating of Overweight and set a new price target of $25.00 from $10.00 previously
LADENBURG THALM/SH SH resumed coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $20.00
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)